Evo Fund Cuts Delta-Fly Pharma Stake to 33.39% After Cashing In Cut-Price Warrants
The Cayman fund acquired warrants priced at ¥0.14 apiece that the filing logs under a 41.14% holding-ratio entry, then exercised and sold into the market through August, trimming its combined stake to 33.39% from 41.97% by September 1.